RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:NK cell immunopotentiators-loaded nanoliposomes enhance ADCC effect for targeted therapy against HER2-positive breast cancer.
NK cell immunopotentiators-loaded nanoliposomes enhance ADCC effect for targeted therapy against HER2-positive breast cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
曲妥珠单抗是HER2阳性(HER2+)乳腺癌一线治疗的基石;然而,由于治疗开始后约一年内出现耐药,尤其是在疗效有限的转移性疾病晚期病例中,这构成了重大挑战。
我们采用单细胞测序和生物信息学分析对HER2+乳腺癌患者的肿瘤组织进行研究,阐明了肿瘤对曲妥珠单抗反应降低的一个关键机制:肿瘤微环境(TME)中自然杀伤(NK)细胞的浸润和活性降低。为了克服这一障碍,我们精心筛选了两种强效免疫调节肽TKD和IP-10p,已知它们可募集NK细胞并增强其活性。通过体外实验,我们证实,增强NK细胞的肿瘤浸润和活性可导致抗体依赖性细胞介导的细胞毒性(ADCC)效应增强,从而放大曲妥珠单抗的抗肿瘤活性。
在此基础发现之上,我们进一步设计了靶向HER2的pH敏感纳米脂质体,以包封TKD和IP-10p肽。新设计的纳米脂质体与NK细胞补充治疗联合,策略性地用于接受曲妥珠单抗治疗的HER2+乳腺癌模型中,产生了显著的抗肿瘤反应,表明该联合策略有效重新激活了抗肿瘤免疫反应。本质上,本研究不仅强调了由trastuzumab介导的ADCC效应减弱与HER2+乳腺癌耐药发生之间的关键联系,还证明了利用HER2靶向纳米脂质体递送NK细胞免疫增强剂可显著增强NK细胞的功能活性及其在TME内的浸润,最终通过增强ADCC效应提高trastuzumab的抗肿瘤疗效。
Trastuzumab serves as a cornerstone of first-line therapy for HER2-positive (HER2 + ) breast cancer; however, a significant challenge arises due to the emergence of resistance within approximately one year of commencement of treatment, particularly in advanced cases with metastatic disease where its efficacy is limited.
Our investigation into the tumor tissue from HER2 + breast cancer patients, employing single-cell sequencing and bioinformatics analysis, has elucidated a crucial mechanism underlying the reduced responsiveness of tumors to trastuzumab: the diminished infiltration and activity of natural killer (NK) cells within the tumor microenvironment (TME). To counteract this impediment, we meticulously selected two potent immune-modulating peptides TKD and IP-10p, which are known to recruit and enhance the activity of NK cells. Through in vitro experiments, we substantiated that bolstering the tumor infiltration and activity of NK cells can lead to an enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) effect, thereby amplifying the anti-tumor activity of trastuzumab. Building upon this foundational discovery, we further designed HER2-targeted pH-sensitive nanoliposomes to encapsulate TKD and IP-10p peptides.
The novel designed nanoliposomes were strategically employed in conjunction with NK cell supplement therapy within a HER2 + breast cancer model undergoing trastuzumab treatment, yielding a striking anti-tumor response and indicating that the combination strategy effectively reinvigorated the anti-tumor immune response.
In essence, this study not only underscores a critical link between the diminished ADCC effect mediated by trastuzumab and the development of resistance in HER2 + breast cancer but also demonstrates leveraging HER2-targeted nanoliposomes to deliver NK cell immunopotentiators can significantly enhance the functional activity of NK cells and their infiltration within the TME, culminating in improved antitumor efficacy of trastuzumab through the augmentation of the ADCC effect.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。